Breaking News
Get 40% Off 0
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks. Unlock full list
Close

Evotec AG O.N. (EVTG)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
9.24 -0.32    -3.30%
13:29:22 - Delayed Data. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  DE0005664809 
S/N:  566480
  • Volume: 678,723
  • Bid/Ask: 9.22 / 9.24
  • Day's Range: 9.06 - 9.64
Evotec AG 9.24 -0.32 -3.30%

EVTG Recent Sentiments

 
This page contains information on users’ sentiments for the Evotec AG O.N. stock, which are displayed both on charts of different periods of time and on a detailed table.
BearishBullish
Start Date Username Call Open Rate End Date Chg. %
May 23, 2024 Gerhard Lukas   9.21 +0.33%
May 17, 2024 Herbert Hahn   10.06 +8.15%
May 13, 2024 Dirk SCHÄFFER   9.68 -4.55%
Apr 24, 2024 Gerhard Lukas   9.67 May 17, 2024 @ 9.73 +0.62%
Mar 26, 2024 Mathias Engelmann   13.99 Apr 19, 2024 @ 13.16 -5.93%
Feb 06, 2024 Mathias Engelmann   13.69 Mar 01, 2024 @ 13.92 +1.68%
Jan 02, 2024 Mathias Engelmann   21.02 Jan 26, 2024 @ 14.50 -31.02%
Nov 30, 2023 Mathias Engelmann   18.48 Dec 22, 2023 @ 20.93 +13.26%
Oct 06, 2023 Björn Wyes   17.26 Oct 26, 2023 @ 16.81 +2.61%
Aug 18, 2023 Björn Wyes   20.20 Sep 05, 2023 @ 21.23 -5.10%
Jul 28, 2023 Herbert Hahn   22.53 Nov 30, 2023 @ 18.28 -18.86%
Jun 20, 2023 Björn Wyes   20.70 Jul 28, 2023 @ 22.50 -8.70%
May 26, 2023 Christian Siefert   20.40 Nov 30, 2023 @ 18.28 -10.39%
May 10, 2023 Sonja Spitaler   17.95 Nov 30, 2023 @ 18.28 +1.84%
May 09, 2023 Mathias Engelmann   16.18 Nov 30, 2023 @ 18.28 +12.98%
Apr 14, 2023 Mathias Engelmann   19.98 May 09, 2023 @ 16.29 -18.47%
Mar 29, 2023 Emil György   19.02 Apr 03, 2023 @ 19.52 +2.63%
Mar 28, 2023 Norbert Simon   17.92 Mar 28, 2023 @ 18.40 +2.68%
Mar 07, 2023 Mathias Engelmann   17.99 Mar 31, 2023 @ 19.50 +8.39%
Feb 28, 2023 Emil György   17.45 Mar 06, 2023 @ 17.64 +1.09%
Jan 30, 2023 Mathias Engelmann   18.89 Feb 24, 2023 @ 17.82 -5.66%
Jan 18, 2023 Emil György   18.71 Jan 23, 2023 @ 18.38 -1.76%
Jan 02, 2023 Mathias Engelmann   15.38 Jan 27, 2023 @ 18.63 +21.13%
Dec 28, 2022 Herbert Hahn   14.87 Jan 20, 2023 @ 18.41 -23.81%
Dec 27, 2022 Emil György   15.04 Jan 02, 2023 @ 15.29 +1.66%
Dec 09, 2022 Mathias Engelmann   16.15 Dec 30, 2022 @ 15.39 -4.71%
Nov 29, 2022 Satilmis Ugur   16.62 Dec 23, 2022 @ 15.15 -8.84%
Nov 29, 2022 Christian Siefert   16.85 Dec 23, 2022 @ 15.15 -10.09%
Nov 21, 2022 Wilhelm Fröhle   16.25 Dec 16, 2022 @ 15.56 -4.25%
Nov 17, 2022 Emil György   17.21 Nov 28, 2022 @ 17.00 -1.22%
Sep 26, 2022 Josef Poth   17.82 Oct 21, 2022 @ 17.95 +0.73%
Sep 01, 2022 Jannik Selzer   21.51 Sep 23, 2022 @ 17.70 +17.71%
Aug 24, 2022 Emil György   22.85 Aug 29, 2022 @ 22.37 -2.10%
Aug 02, 2022 Satilmis Ugur   27.27 Aug 26, 2022 @ 22.95 -15.84%
May 13, 2022 Dirk Weinforth   23.90 Jun 03, 2022 @ 25.76 +7.78%
May 11, 2022 Herbert Hahn   21.22 Jun 03, 2022 @ 25.76 +21.39%
Apr 26, 2022 Wolfgang Fettke   23.47 May 20, 2022 @ 25.20 +7.37%
Apr 12, 2022 Mathias Engelmann   26.24 May 06, 2022 @ 22.05 -15.97%
Feb 22, 2022 Mathias Engelmann   25.21 Mar 18, 2022 @ 28.06 +11.31%
Jan 11, 2022 marcel kinsl   38.41 Feb 04, 2022 @ 30.90 -19.55%
Jan 06, 2022 Mathias Engelmann   39.74 Jan 28, 2022 @ 34.80 -12.43%
Jan 04, 2022 Wolfgang Fettke   39.43 Jan 28, 2022 @ 34.80 -11.74%
Nov 29, 2021 Jannik Selzer   41.45 Dec 24, 2021 @ 39.79 -4.00%
Nov 22, 2021 Mathias Engelmann   43.33 Dec 17, 2021 @ 40.88 -5.65%
Oct 28, 2021 Mathias Engelmann   42.44 Nov 19, 2021 @ 42.15 -0.68%
Oct 26, 2021 Jannik Selzer   43.08 Nov 19, 2021 @ 42.15 -2.16%
Oct 08, 2021 Andreas Eishai   39.31 Oct 29, 2021 @ 41.91 +6.61%
Sep 13, 2021 Mathias Engelmann   43.38 Oct 08, 2021 @ 39.53 -8.88%
Sep 06, 2021 Владимир Чухланцев   41.36 Oct 01, 2021 @ 40.99 -0.89%
Aug 11, 2021 Mathias Engelmann   38.30 Sep 03, 2021 @ 41.88 +9.35%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

EVTG Comments

Write your thoughts about Evotec AG
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Bill Boulton
Bill Boulton Feb 19, 2021 10:01AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
To be fair the stock has had large (lazy) short positions for many months and the US DoD deal is not new news. Also, the sceince of  monoclonal antibodies is still not proven. That said, as a pipeline of royalties begin to come through adding to top lines my outlook remains  €50 target in 3 years.
Daimon van Buren
Daimon van Buren Jan 27, 2021 4:00AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
lol railing Melvin Capital left and right
In Sight
Insight Jan 27, 2021 4:00AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Doesnt have anything to do with that here but rather the us military filing in a huge order at evotec for anti bodies against covid (over the next 7 years)
Bill Boulton
Bill Boulton Mar 04, 2019 10:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
155171057981821.jpg
The valuation is very much a "sum of the parts" not a not a future valuation. The potentials from a series of bolt on company purchases and ongoing strategic alliances will see a valuation of €10Bn within the next 5 years. What is not priced in to the current valuation is the vision of the management  and shear quality of the science.. . Volatility is an issue so hold on to your hat !!. . Still not convinced ? Where else could you have got 50%+ return on stocks for the past three years ??
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email